Nothing said here yet.
to join the conversation.
NTRA partners with TransCode Therapeutics to use Signatera MRD testing in a Phase 2a colorectal cancer trial, aiming to accelerate enrollment and research.
Allowances of Patent Applications in Australia and Japan support differentiated RNA platform for targeted cancer therapy and immune modulation BOSTON, Sept. 22, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc.
Learn how TransCode Therapeutics is advancing RNA therapeutics, cancer vaccines, and immuno-oncology programs designed to address advanced and metastatic cancersManagement to discuss TTX-MC138, the ongoing Phase 2a colorectal cancer trial, tumor-targeted RNA delivery, and multiple upcoming clinical catalystsORLANDO, FL / ACCESS Newswire / September 16, 2026 / RedChip Companies will host an investor webinar today, September 16, 2026, at 4:15 p.
Tom Fitzgerald, Chief Financial Officer, Announces his Retirement John Tattory, to become Interim Chief Financial Officer BOSTON, Sept. 10, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc.
Learn how TransCode Therapeutics is advancing RNA therapeutics, cancer vaccines, and immuno-oncology programs designed to address advanced and metastatic cancersManagement to discuss TTX-MC138, the ongoing Phase 2a colorectal cancer trial, tumor-targeted RNA delivery, and multiple upcoming clinical catalystsORLANDO, FL / ACCESS Newswire / September 3, 2026 / RedChip Companies will host an investor webinar on Wednesday, September 16, 2026, at 4:15 p.
Published study in Cancers highlights therapeutic potential of targeting microRNA-10b in bone metastasis with TransCode's lead therapeutic candidate BOSTON, Aug. 31, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc.